Concepts (208)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain | 24 | 2023 | 331 | 4.270 |
Why?
|
| Alzheimer Disease | 27 | 2026 | 409 | 3.870 |
Why?
|
| Aging | 24 | 2026 | 352 | 2.690 |
Why?
|
| Cognitive Dysfunction | 13 | 2026 | 235 | 2.420 |
Why?
|
| Aged, 80 and over | 46 | 2026 | 1034 | 2.340 |
Why?
|
| Membrane Transport Proteins | 4 | 2017 | 29 | 1.950 |
Why?
|
| Cognition | 15 | 2021 | 337 | 1.920 |
Why?
|
| Female | 51 | 2026 | 3346 | 1.890 |
Why?
|
| Cognition Disorders | 11 | 2019 | 237 | 1.870 |
Why?
|
| Aged | 42 | 2026 | 1860 | 1.860 |
Why?
|
| Male | 48 | 2023 | 3399 | 1.750 |
Why?
|
| DNA Methylation | 6 | 2021 | 72 | 1.620 |
Why?
|
| Humans | 56 | 2026 | 5837 | 1.550 |
Why?
|
| Independent Living | 5 | 2021 | 62 | 1.490 |
Why?
|
| Health Literacy | 4 | 2023 | 28 | 1.430 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2018 | 123 | 1.340 |
Why?
|
| Longitudinal Studies | 22 | 2023 | 363 | 1.210 |
Why?
|
| Dementia | 5 | 2023 | 127 | 1.040 |
Why?
|
| Cohort Studies | 16 | 2020 | 406 | 1.030 |
Why?
|
| Apolipoprotein E4 | 4 | 2018 | 92 | 0.990 |
Why?
|
| TDP-43 Proteinopathies | 3 | 2020 | 20 | 0.920 |
Why?
|
| Neuropsychological Tests | 16 | 2020 | 309 | 0.890 |
Why?
|
| Neurodegenerative Diseases | 3 | 2021 | 39 | 0.720 |
Why?
|
| Metacognition | 1 | 2021 | 3 | 0.700 |
Why?
|
| Cerebral Infarction | 3 | 2016 | 29 | 0.670 |
Why?
|
| Limbic Encephalitis | 1 | 2020 | 4 | 0.650 |
Why?
|
| Proteins | 1 | 2020 | 22 | 0.650 |
Why?
|
| Adaptation, Psychological | 1 | 2020 | 41 | 0.640 |
Why?
|
| Genetic Variation | 2 | 2017 | 23 | 0.620 |
Why?
|
| DNA-Binding Proteins | 8 | 2020 | 94 | 0.620 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 9 | 0.610 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2020 | 21 | 0.600 |
Why?
|
| Gene Expression | 2 | 2019 | 64 | 0.560 |
Why?
|
| Cerebral Amyloid Angiopathy | 2 | 2015 | 28 | 0.560 |
Why?
|
| Haplotypes | 2 | 2020 | 19 | 0.560 |
Why?
|
| Brain Infarction | 1 | 2017 | 23 | 0.530 |
Why?
|
| RNA, Messenger | 1 | 2017 | 87 | 0.530 |
Why?
|
| Literacy | 1 | 2017 | 9 | 0.520 |
Why?
|
| Polymorphism, Genetic | 1 | 2017 | 26 | 0.520 |
Why?
|
| Apolipoprotein E3 | 1 | 2017 | 5 | 0.510 |
Why?
|
| Homozygote | 1 | 2017 | 6 | 0.510 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 26 | 0.470 |
Why?
|
| Prefrontal Cortex | 1 | 2016 | 36 | 0.460 |
Why?
|
| Antiporters | 1 | 2015 | 4 | 0.440 |
Why?
|
| HLA-DRB5 Chains | 1 | 2015 | 4 | 0.440 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2015 | 6 | 0.440 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2015 | 6 | 0.440 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 9 | 0.440 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 30 | 0.430 |
Why?
|
| Quality of Life | 1 | 2015 | 108 | 0.420 |
Why?
|
| Risk Factors | 6 | 2018 | 499 | 0.420 |
Why?
|
| Genotype | 4 | 2018 | 114 | 0.400 |
Why?
|
| Lewy Bodies | 5 | 2019 | 56 | 0.390 |
Why?
|
| Hippocampus | 4 | 2019 | 61 | 0.390 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 333 | 0.390 |
Why?
|
| Disease Progression | 6 | 2019 | 157 | 0.390 |
Why?
|
| Disabled Persons | 2 | 2023 | 24 | 0.350 |
Why?
|
| Decision Making | 4 | 2022 | 49 | 0.340 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2023 | 207 | 0.340 |
Why?
|
| Apolipoproteins E | 4 | 2020 | 55 | 0.340 |
Why?
|
| Nerve Tissue Proteins | 2 | 2020 | 52 | 0.320 |
Why?
|
| Genome-Wide Association Study | 6 | 2016 | 66 | 0.320 |
Why?
|
| Gait | 2 | 2023 | 93 | 0.320 |
Why?
|
| Cerebrovascular Disorders | 2 | 2021 | 19 | 0.310 |
Why?
|
| Autopsy | 6 | 2019 | 67 | 0.310 |
Why?
|
| Mobility Limitation | 2 | 2021 | 16 | 0.280 |
Why?
|
| Parkinsonian Disorders | 2 | 2021 | 43 | 0.280 |
Why?
|
| Epigenesis, Genetic | 2 | 2021 | 28 | 0.270 |
Why?
|
| Proportional Hazards Models | 6 | 2017 | 71 | 0.260 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 187 | 0.240 |
Why?
|
| Middle Aged | 6 | 2017 | 1775 | 0.240 |
Why?
|
| Plaque, Amyloid | 2 | 2016 | 29 | 0.230 |
Why?
|
| Memory Disorders | 2 | 2017 | 48 | 0.230 |
Why?
|
| Lewy Body Disease | 3 | 2018 | 29 | 0.230 |
Why?
|
| Genetic Association Studies | 2 | 2015 | 32 | 0.220 |
Why?
|
| Residence Characteristics | 3 | 2015 | 43 | 0.220 |
Why?
|
| Memory, Episodic | 3 | 2019 | 26 | 0.200 |
Why?
|
| Sclerosis | 3 | 2019 | 26 | 0.200 |
Why?
|
| Membrane Proteins | 2 | 2020 | 38 | 0.190 |
Why?
|
| Crime Victims | 1 | 2022 | 9 | 0.180 |
Why?
|
| Sex Characteristics | 2 | 2022 | 36 | 0.180 |
Why?
|
| Blood Glucose | 1 | 2022 | 30 | 0.180 |
Why?
|
| Depression | 2 | 2013 | 113 | 0.180 |
Why?
|
| Hypertension | 1 | 2022 | 35 | 0.180 |
Why?
|
| Alleles | 3 | 2018 | 89 | 0.180 |
Why?
|
| Perception | 2 | 2019 | 30 | 0.180 |
Why?
|
| Executive Function | 1 | 2021 | 31 | 0.170 |
Why?
|
| Heterozygote | 3 | 2018 | 59 | 0.170 |
Why?
|
| Risk-Taking | 2 | 2011 | 16 | 0.170 |
Why?
|
| Logistic Models | 3 | 2017 | 109 | 0.170 |
Why?
|
| Memory, Short-Term | 2 | 2019 | 37 | 0.170 |
Why?
|
| Olfaction Disorders | 2 | 2011 | 8 | 0.170 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2020 | 4 | 0.170 |
Why?
|
| GPI-Linked Proteins | 1 | 2020 | 4 | 0.170 |
Why?
|
| Molecular Chaperones | 1 | 2020 | 5 | 0.170 |
Why?
|
| Vesicular Transport Proteins | 1 | 2020 | 5 | 0.160 |
Why?
|
| Actinin | 1 | 2020 | 7 | 0.160 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2020 | 6 | 0.160 |
Why?
|
| Neuropeptides | 1 | 2020 | 12 | 0.160 |
Why?
|
| Epoxide Hydrolases | 1 | 2020 | 7 | 0.160 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 17 | 0.160 |
Why?
|
| RNA Splicing Factors | 1 | 2020 | 3 | 0.160 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2015 | 72 | 0.160 |
Why?
|
| Linear Models | 2 | 2018 | 64 | 0.160 |
Why?
|
| Mental Status Schedule | 2 | 2017 | 32 | 0.160 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 66 | 0.150 |
Why?
|
| Educational Status | 2 | 2017 | 60 | 0.150 |
Why?
|
| CpG Islands | 2 | 2021 | 21 | 0.150 |
Why?
|
| Transcriptome | 1 | 2019 | 12 | 0.150 |
Why?
|
| Mortality | 3 | 2014 | 22 | 0.140 |
Why?
|
| Range of Motion, Articular | 1 | 2019 | 136 | 0.140 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2018 | 8 | 0.140 |
Why?
|
| Temporal Lobe | 1 | 2018 | 17 | 0.140 |
Why?
|
| Frontotemporal Lobar Degeneration | 1 | 2018 | 7 | 0.140 |
Why?
|
| Memory | 2 | 2015 | 61 | 0.140 |
Why?
|
| Risk | 2 | 2015 | 60 | 0.130 |
Why?
|
| Learning | 1 | 2018 | 23 | 0.130 |
Why?
|
| Protein-Arginine Deiminases | 1 | 2017 | 8 | 0.130 |
Why?
|
| Knee Joint | 1 | 2019 | 118 | 0.130 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 10 | 0.130 |
Why?
|
| Cognitive Aging | 1 | 2018 | 27 | 0.130 |
Why?
|
| United States | 2 | 2017 | 502 | 0.130 |
Why?
|
| alpha-Macroglobulins | 1 | 2017 | 11 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 13 | 0.130 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 24 | 0.130 |
Why?
|
| Motor Activity | 2 | 2015 | 83 | 0.130 |
Why?
|
| Genetic Linkage | 1 | 2017 | 7 | 0.130 |
Why?
|
| Diagnosis | 1 | 2017 | 5 | 0.130 |
Why?
|
| Illinois | 1 | 2017 | 52 | 0.130 |
Why?
|
| Genotyping Techniques | 1 | 2017 | 6 | 0.130 |
Why?
|
| Neuropathology | 1 | 2017 | 17 | 0.130 |
Why?
|
| Time Factors | 2 | 2015 | 374 | 0.120 |
Why?
|
| Geriatric Assessment | 2 | 2015 | 59 | 0.120 |
Why?
|
| Prognosis | 1 | 2017 | 138 | 0.120 |
Why?
|
| Genome, Human | 1 | 2016 | 10 | 0.120 |
Why?
|
| Postmortem Changes | 1 | 2016 | 9 | 0.120 |
Why?
|
| Chromatin | 1 | 2016 | 7 | 0.120 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2016 | 16 | 0.120 |
Why?
|
| White Matter | 1 | 2016 | 24 | 0.120 |
Why?
|
| Smell | 1 | 2015 | 8 | 0.120 |
Why?
|
| Neurons | 2 | 2013 | 90 | 0.120 |
Why?
|
| Markov Chains | 1 | 2015 | 10 | 0.110 |
Why?
|
| Biomarkers | 1 | 2016 | 141 | 0.110 |
Why?
|
| Personality | 1 | 2015 | 14 | 0.110 |
Why?
|
| Risk Assessment | 1 | 2015 | 112 | 0.110 |
Why?
|
| Mesencephalon | 1 | 2013 | 11 | 0.100 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 203 | 0.100 |
Why?
|
| Sleep Wake Disorders | 1 | 2012 | 30 | 0.090 |
Why?
|
| Neural Pathways | 1 | 2011 | 12 | 0.090 |
Why?
|
| Brain Mapping | 1 | 2011 | 37 | 0.090 |
Why?
|
| Odorants | 1 | 2010 | 5 | 0.080 |
Why?
|
| Exercise | 2 | 2023 | 96 | 0.080 |
Why?
|
| Self Report | 2 | 2022 | 53 | 0.070 |
Why?
|
| Incidence | 2 | 2021 | 165 | 0.070 |
Why?
|
| Disability Evaluation | 2 | 2019 | 60 | 0.060 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2026 | 3 | 0.060 |
Why?
|
| Proteomics | 1 | 2026 | 10 | 0.060 |
Why?
|
| Nerve Net | 2 | 2019 | 18 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2016 | 411 | 0.050 |
Why?
|
| Sex Factors | 2 | 2016 | 129 | 0.050 |
Why?
|
| Hand Strength | 1 | 2023 | 11 | 0.050 |
Why?
|
| Walking | 1 | 2023 | 53 | 0.050 |
Why?
|
| Activities of Daily Living | 1 | 2023 | 75 | 0.050 |
Why?
|
| Fraud | 1 | 2022 | 6 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2022 | 25 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2022 | 48 | 0.050 |
Why?
|
| Epigenomics | 1 | 2021 | 8 | 0.040 |
Why?
|
| Phenotype | 1 | 2021 | 96 | 0.040 |
Why?
|
| Adult | 2 | 2015 | 1670 | 0.040 |
Why?
|
| Myelin Sheath | 1 | 2020 | 5 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2020 | 10 | 0.040 |
Why?
|
| Lysosomes | 1 | 2020 | 10 | 0.040 |
Why?
|
| Amyloid beta-Peptides | 1 | 2020 | 41 | 0.040 |
Why?
|
| Fractals | 1 | 2019 | 3 | 0.040 |
Why?
|
| Neuroimaging | 1 | 2019 | 22 | 0.040 |
Why?
|
| Muscle Strength | 1 | 2019 | 23 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 32 | 0.040 |
Why?
|
| Arteriolosclerosis | 1 | 2018 | 14 | 0.040 |
Why?
|
| tau Proteins | 1 | 2018 | 36 | 0.040 |
Why?
|
| alpha-Synuclein | 1 | 2018 | 36 | 0.030 |
Why?
|
| Dementia, Vascular | 1 | 2018 | 7 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 98 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2017 | 22 | 0.030 |
Why?
|
| Tuberous Sclerosis | 1 | 2017 | 5 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 71 | 0.030 |
Why?
|
| Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 1 | 2016 | 4 | 0.030 |
Why?
|
| Receptors, Complement 3b | 1 | 2016 | 8 | 0.030 |
Why?
|
| Zinc Fingers | 1 | 2016 | 8 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 13 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 181 | 0.030 |
Why?
|
| Awareness | 1 | 2015 | 13 | 0.030 |
Why?
|
| Histones | 1 | 2014 | 5 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2014 | 9 | 0.030 |
Why?
|
| Raphe Nuclei | 1 | 2013 | 5 | 0.030 |
Why?
|
| Locus Coeruleus | 1 | 2013 | 6 | 0.030 |
Why?
|
| Ventral Tegmental Area | 1 | 2013 | 6 | 0.030 |
Why?
|
| Cell Count | 1 | 2013 | 16 | 0.030 |
Why?
|
| Mutation | 1 | 2014 | 101 | 0.030 |
Why?
|
| Substantia Nigra | 1 | 2013 | 25 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2013 | 1 | 0.020 |
Why?
|
| Actigraphy | 1 | 2012 | 12 | 0.020 |
Why?
|
| Rest | 1 | 2012 | 15 | 0.020 |
Why?
|
| Games, Experimental | 1 | 2011 | 5 | 0.020 |
Why?
|
| Probability | 1 | 2011 | 22 | 0.020 |
Why?
|
| Oxygen | 1 | 2011 | 13 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 46 | 0.020 |
Why?
|
| Sleep | 1 | 2012 | 88 | 0.020 |
Why?
|
| Death | 1 | 2010 | 11 | 0.020 |
Why?
|